AcrySof® IQ PanOptix
Maryland Vision Institute’s PanOptix Technology
Patients undergoing cataract surgery at Maryland Vision Institute now have access to a breakthrough ‘trifocal’ lens implant called the AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL), that recently received approval by the Food & Drug Administration for implantation in the United States. During investigational clinical trials, PanOptix patients were able to enjoy uninterrupted vision at near, intermediate and distance. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.
The PanOptix lens is the first trifocal IOL of its kind capable of delivering a unique combination of near, intermediate and distance vision to patients while significantly reducing your need for glasses after cataract surgery. This trifocal lens implant is designed for patients with active lifestyles who require good vision at all ranges.
This would include everything from viewing mobile devices & computer screens to intermediate and high-quality distance vision in a range of lighting conditions. The PanOptix lens uses ENLIGHTEN®Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision.
This multifocal IOL is used to focus images clearly onto the back of your eye to allow clear vision after cataract removal. In addition, the center of this unique Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal – or single vision – lens would provide.
Medicare now allows patients to upgrade their vision using advanced lens implant technology like the PanOptix lens. This lens is fully approved by Medicare, but the PanOptix IOL is not covered by insurance. So patients are responsible for the out-of-pocket costs associated with Premium IOL technology like the PanOptix.